Just as we celebrate a young girl's first period as a rite of passage, menopause deserves recognition as the next major ...

Hot flashes happened less often and were less severe in women who took elinzanetant compared to those who took a placebo. The ...

CHICAGO (WLS) -- When it comes to women's health, generations have avoided talking openly about menopause. It was considered taboo, which is wild, because roughly half of the population will ...

Dr. Sarah De La Torre, a double board-certified physician and the clinical lead for Respin, joins TODAY’s Jenna Bush Hager ...

Despite a renaissance in menopause awareness, the over-medicalisation of women’s midlife health threatens to eclipse foundational interventions like physical activity. Menopause is a pivotal milestone ...

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive ...

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

Although rarely used in the US, it may be time to revisit HRT for women with MS, as it eases overlapping symptoms and offers a justifiable benefit-risk profile, experts say.

When the FDA approved fezolinetant for treating moderate to severe hot flashes in menopausal women, the news made headlines.

Menopause – which impacts not only half of the global population but also one of the fastest-growing US workforce ...